Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 699

1.

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, Pföhler C, Herbst R, Schilling B, Blank C, Becker JC, Paschen A, Zimmer L, Livingstone E, Horn PA, Rebmann V.

Ann Oncol. 2020 Jan;31(1):144-152. doi: 10.1016/j.annonc.2019.09.005.

PMID:
31912789
2.

Frontline immunotherapy for NSCLC - the tale of the tail.

Chiang AC, Herbst RS.

Nat Rev Clin Oncol. 2020 Feb;17(2):73-74. doi: 10.1038/s41571-019-0317-y. No abstract available.

PMID:
31907372
3.

MuSk function during health and disease.

Herbst R.

Neurosci Lett. 2020 Jan 18;716:134676. doi: 10.1016/j.neulet.2019.134676. Epub 2019 Dec 4. Review.

4.

IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development.

Li A, Herbst RH, Canner D, Schenkel JM, Smith OC, Kim JY, Hillman M, Bhutkar A, Cuoco MS, Rappazzo CG, Rogers P, Dang C, Jerby-Arnon L, Rozenblatt-Rosen O, Cong L, Birnbaum M, Regev A, Jacks T.

Cell Rep. 2019 Dec 3;29(10):2998-3008.e8. doi: 10.1016/j.celrep.2019.10.120.

5.

Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.

Rodríguez Cruz PM, Cossins J, Cheung J, Maxwell S, Jayawant S, Herbst R, Waithe D, Kornev AP, Palace J, Beeson D.

Hum Mutat. 2019 Nov 25. doi: 10.1002/humu.23949. [Epub ahead of print]

PMID:
31765060
6.

Small molecule combats cancer-causing KRAS protein at last.

Herbst RS, Schlessinger J.

Nature. 2019 Nov;575(7782):294-295. doi: 10.1038/d41586-019-03242-8. No abstract available.

PMID:
31705127
7.

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K.

J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3.

8.

THE EFFECTS OF PERIOPERATIVE DEXAMETHASONE ON GLYCEMIC CONTROL AND POSTOPERATIVE OUTCOMES.

Herbst RA, Telford OT, Hunting J, Bullock WM, Manning E, Hong BD, D'Alessio DA, Setji TL.

Endocr Pract. 2019 Oct 25. doi: 10.4158/EP-2019-0252. [Epub ahead of print]

PMID:
31652101
9.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.

Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, Schalper KA, Rimm DL.

Clin Cancer Res. 2019 Oct 15. doi: 10.1158/1078-0432.CCR-19-1040. [Epub ahead of print]

PMID:
31615933
10.

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger SN, Herbst RS, Schalper KA, Rimm DL.

J Thorac Oncol. 2019 Dec;14(12):2084-2096. doi: 10.1016/j.jtho.2019.09.014. Epub 2019 Oct 9.

PMID:
31605795
11.

Calcitonin Gene-Related Peptide Negatively Regulates Alarmin-Driven Type 2 Innate Lymphoid Cell Responses.

Wallrapp A, Burkett PR, Riesenfeld SJ, Kim SJ, Christian E, Abdulnour RE, Thakore PI, Schnell A, Lambden C, Herbst RH, Khan P, Tsujikawa K, Xavier RJ, Chiu IM, Levy BD, Regev A, Kuchroo VK.

Immunity. 2019 Oct 15;51(4):709-723.e6. doi: 10.1016/j.immuni.2019.09.005. Epub 2019 Oct 8.

PMID:
31604686
12.

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, Sunderkötter C, Kaatz M, Schatton K, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Verver D, Martus P, Garbe C; German Dermatologic Cooperative Oncology Group.

J Clin Oncol. 2019 Nov 10;37(32):3000-3008. doi: 10.1200/JCO.18.02306. Epub 2019 Sep 26.

PMID:
31557067
13.

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW.

J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8.

14.

Childrens' and Parents' Willingness to Join a Smartphone-Based Emergency Response Community for Anaphylaxis: Survey.

Khalemsky M, Schwartz DG, Silberg T, Khalemsky A, Jaffe E, Herbst R.

JMIR Mhealth Uhealth. 2019 Aug 27;7(8):e13892. doi: 10.2196/13892.

15.

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S.

Cell. 2019 Aug 22;178(5):1189-1204.e23. doi: 10.1016/j.cell.2019.07.044.

PMID:
31442407
16.

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Haematologica. 2019 Aug 14. pii: haematol.2019.222323. doi: 10.3324/haematol.2019.222323. [Epub ahead of print]

17.

The Immunoscore: Colon Cancer and Beyond.

Angell HK, Bruni D, Barrett JC, Herbst R, Galon J.

Clin Cancer Res. 2020 Jan 15;26(2):332-339. doi: 10.1158/1078-0432.CCR-18-1851. Epub 2019 Aug 14. Review.

PMID:
31413009
18.

Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis.

Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, Herbst RH, Rogel N, Slyper M, Waldman J, Sud M, Andrews E, Velonias G, Haber AL, Jagadeesh K, Vickovic S, Yao J, Stevens C, Dionne D, Nguyen LT, Villani AC, Hofree M, Creasey EA, Huang H, Rozenblatt-Rosen O, Garber JJ, Khalili H, Desch AN, Daly MJ, Ananthakrishnan AN, Shalek AK, Xavier RJ, Regev A.

Cell. 2019 Jul 25;178(3):714-730.e22. doi: 10.1016/j.cell.2019.06.029.

PMID:
31348891
19.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

20.

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS.

J Thorac Oncol. 2019 Oct;14(10):1853-1859. doi: 10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11.

PMID:
31302234
21.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.

PMID:
31301962
22.

Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Koneczny I, Herbst R.

Cells. 2019 Jul 2;8(7). pii: E671. doi: 10.3390/cells8070671. Review.

23.

Quantification of In Vivo Target Engagement Using Microfluidic Activity-Based Protein Profiling.

Reardon HT, Herbst RA, Henry CL, Herbst DM, Ngo N, Cisar JS, Weber OD, Niphakis MJ, O'Neill GP.

SLAS Technol. 2019 Oct;24(5):489-498. doi: 10.1177/2472630319852303. Epub 2019 Jun 14.

PMID:
31199699
24.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.

J Thorac Oncol. 2019 Oct;14(10):1847-1852. doi: 10.1016/j.jtho.2019.05.041. Epub 2019 Jun 11.

PMID:
31195180
25.

USING THE ATA AND ACR TI-RADS SONOGRAPHIC CLASSIFICATIONS AS ADJUNCTIVE PREDICTORS OF MALIGNANCY FOR INDETERMINATE THYROID NODULES.

Ahmadi S, Herbst R, Oyekunle T, Jiang X', Strickland K, Roman S, Sosa JA.

Endocr Pract. 2019 Sep;25(9):908-917. doi: 10.4158/EP-2018-0559. Epub 2019 Jun 6.

PMID:
31170369
26.

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA.

J Thorac Oncol. 2019 Oct;14(10):1839-1846. doi: 10.1016/j.jtho.2019.05.029. Epub 2019 May 31.

PMID:
31158500
27.

Treatment of Maternal Depression in Pediatric Primary Care.

Herbst RB, Ammerman RT, Perry SP, Zion CE, Rummel MK, McClure JM, Stark LJ.

Clin Pediatr (Phila). 2019 Nov;58(13):1436-1439. doi: 10.1177/0009922819850469. Epub 2019 May 21. No abstract available.

PMID:
31113226
28.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

29.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
30.

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.

Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaar6584. doi: 10.1126/scitranslmed.aar6584.

PMID:
31019027
31.

Nurse-Led Telephone Follow-Up to Improve Parent Promotion of Healthy Behaviors in Young Children With Motivational Interviewing Techniques.

Schlottmann H, Broome M, Herbst R, Burkhardt MC, Mescher A.

J Pediatr Health Care. 2019 Sep - Oct;33(5):545-554. doi: 10.1016/j.pedhc.2019.02.003. Epub 2019 Mar 27.

PMID:
30926151
32.

Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".

Wilson FH, Herbst RS.

Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Epub 2019 Mar 13. No abstract available.

PMID:
30865435
33.

Immune Checkpoint Inhibitor-Associated Pericarditis.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL.

J Thorac Oncol. 2019 Jun;14(6):1102-1108. doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

PMID:
30851443
34.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

35.

Effective Implementation of Culturally Appropriate Tools in Addressing Overweight and Obesity in an Urban Underserved Early Childhood Population in Pediatric Primary Care.

Herbst RB, Khalsa AS, Schlottmann H, Kerrey MK, Glass K, Burkhardt MC.

Clin Pediatr (Phila). 2019 May;58(5):511-520. doi: 10.1177/0009922819832088. Epub 2019 Mar 6.

PMID:
30841719
36.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.

PMID:
30833750
37.

The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center.

Khuri FR, Herbst RS.

Cancer. 2019 May 15;125(10):1593-1596. doi: 10.1002/cncr.32045. Epub 2019 Mar 2. No abstract available.

PMID:
30825386
38.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Review.

PMID:
30824587
39.

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S.

Cell Syst. 2019 Feb 27;8(2):136-151.e7. doi: 10.1016/j.cels.2019.01.004. Epub 2019 Feb 20.

PMID:
30797773
40.

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS.

J Thorac Oncol. 2019 Jun;14(6):1046-1060. doi: 10.1016/j.jtho.2019.02.004. Epub 2019 Feb 13.

41.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H.

J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2.

PMID:
30721797
42.

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer.

Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP.

J Geriatr Oncol. 2019 Jul;10(4):669-672. doi: 10.1016/j.jgo.2019.01.016. Epub 2019 Feb 2. No abstract available.

PMID:
30718180
43.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 May;14(5):793-801. doi: 10.1016/j.jtho.2019.01.016. Epub 2019 Jan 31. Erratum in: J Thorac Oncol. 2019 Jul;14(7):1306.

PMID:
30711649
44.

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy.

Varkey R, Du Q, Karnell JL, Xiao X, Casey KA, Woods R, Rosenthal K, Wilson S, Dall'Acqua WF, Wu H, Herbst R, Ettinger R, Damschroder M.

PLoS One. 2019 Jan 25;14(1):e0211236. doi: 10.1371/journal.pone.0211236. eCollection 2019.

45.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

PMID:
30657853
46.

Tumor-Infiltrating Lymphocytes-Location for Prognostic Evaluation.

Peled M, Onn A, Herbst RS.

Clin Cancer Res. 2019 Mar 1;25(5):1449-1451. doi: 10.1158/1078-0432.CCR-18-3803. Epub 2018 Dec 19.

PMID:
30567833
47.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E.

Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Review.

48.

A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).

Corrie PG, Terheyden P, Ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P.

Br J Dermatol. 2019 May;180(5):1254-1255. doi: 10.1111/bjd.17465. Epub 2019 Feb 10. No abstract available.

PMID:
30488430
49.

CD19-positive antibody-secreting cells provide immune memory.

Groves CJ, Carrell J, Grady R, Rajan B, Morehouse CA, Halpin R, Wang J, Wu J, Shrestha Y, Rayanki R, Kolbeck R, Wang Y, Herbst R.

Blood Adv. 2018 Nov 27;2(22):3163-3176. doi: 10.1182/bloodadvances.2017015172.

50.

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.

Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S, Vinall LMK, Kemp BP, Kasturiangan S, Rees DG, Grant E, Hinrichs MJ, Eck S, DiGiandomenico A, Jack Borrok M, Ly N, Xiong X, Gonzalez C, Morehouse C, Wang Y, Zhou Y, Cann J, Zhao W, Koelkebeck H, Okubo K, Mayadas TN, Howe D, Griffiths J, Kolbeck R, Herbst R, Sims GP.

Ann Rheum Dis. 2019 Feb;78(2):228-237. doi: 10.1136/annrheumdis-2018-213523. Epub 2018 Nov 20.

Supplemental Content

Loading ...
Support Center